Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia

NCT00017589 is registered in ClinicalTrials.gov with Genta Incorporated as lead sponsor.

NCT NCT00017589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00017589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia
Lead sponsor
Genta Incorporated
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2000
Completion date
May 31, 2006
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia